    
|
   
 IRM is transforming the treatment of cardiac arrhythmias and working to save thousands of lives each year.
CORPORATE OFFICERS
BOARD OF DIRECTORS
CORPORATE OFFICERS Daniel A. Pelak Terry Ransbury Ransbury brings 20 years of management and product development experience in the medical device industry to his position, including assignments at early-stage as well as Fortune 500 companies. He was the principal designer of the medical instrumentation device for programming implantable defibrillators at Ventritex, Inc. As clinical manager at BioSense, he oversaw the field introduction of the industry-standard CARTO 3D electrophysiological mapping and ablation system. Each company was acquired for more than $350 million during his tenure. He also co-founded and served as chief technology officer of Resolution Medical, Inc., which developed a high-resolution, body surface mapping system to detect, localize, and quantify arrhythmic and ischemic cardiac events. Back to top. Stephen C. Masson Steve Masson joined IRM in 2003, leading the company’s product development, product planning, operations, and early relationships with key technology and funding partners and consultants. He draws from more than 25 years experience in the design and manufacture of implantable medical devices, including pacemakers and defibrillators. At Ventritex, Inc., Masson served as vice president of product development, overseeing the team that created a series of highly advanced implantable cardiac devices, resulting in the company attaining as much as a 35-percent U.S. market share and more than $125 million in annual revenue. During his more than 10 years at Ventritex, he directed hardware, software, and mechanical development for principal product lines and provided operations and engineering support for products in manufacturing. Previously, he was vice president of research and development at HeartWare, Inc., a cardiac-assist device company, and developed pacemakers at Cordis Corporation. Back to top. Benny Ward With more than 15 years of financial operations and management experience, Benny Ward joined IRM in 2006. He most recently spent more than nine years at Closure Medical Corporation, a world-leading, publicly traded developer and manufacturer of biomaterial-based medical adhesives with end-user annual revenue of approximately $125 million. He joined Closure Medical in 1996 as controller and became chief financial officer in 2000, serving as a key member of the management team from the company’s successful initial public offering through its 2005 sale to Johnson & Johnson. Before joining Closure Medical, he spent three years as an auditor for Price Waterhouse. A Certified Public Accountant, he earned bachelor’s degrees in accounting and political science from East Carolina University. Back to top.
BOARD OF DIRECTORS William N. Starling, Chairman William N. Starling is Chief Executive Officer of Synecor, LLC, (Synecor) a business generator of new Life Science companies based in Research Triangle Park (RTP), North Carolina, Santa Rosa, California, and Portola Valley, California. Synecor (www.synecor.com) has significant academic, scientific, physician, venture capital, corporate, and investment banking partnerships and is focusing its efforts on the identification and development of proprietary, disruptive technologies with extraordinary market potential in the life sciences field. Nathan Every, M.D., Director Dr. Nathan Every is a cardiologist who evaluates opportunities in biotechnology and medical devices for Frazier Healthcare Ventures. He joined the firm in 1999, became a partner in 2001, and was instrumental in the formation of incubator Synecor LLC. Previously, he was an associate professor of medicine and the director of the Cardiovascular Outcomes Research Center (CORC) at the University of Washington. Every has served on the executive committees of multiple randomized clinical trials in cardiovascular medicine, including the COURAGE trial funded by Merck & Co., Inc., and the OPUS trial funded by Johnson & Johnson. His findings have been published in more than 50 scientific publications, including The New England Journal of Medicine, JAMA, and The Lancet. He serves on national committees for the American College of Cardiology, American Heart Association, and U.S. Department of Veterans Affairs. Board certified in internal medicine and cardiovascular medicine, he earned his medical degree from Emory University and master’s degree from the University of Washington’s School of Public Health. Back to top. John Maroney, Director John Maroney focuses on medical device and diagnostic investments for Delphi Ventures. Before joining the firm in 2003, he was president and chief executive officer of EndoTex Interventional Systems, Inc. He previously held a variety of senior management positions, including president and general manager of EP Technologies, and vice president of operations at both Boston Scientific Corporation and Cardiovascular Imaging Systems (CVIS). While at CVIS, he was a key member of the senior management team during the company’s initial public offering and eventual acquisition by Boston Scientific. In addition to his IRM duties, he serves on the board of directors of TriVascular, Inc., and as chairman of the board of EndoTex. He earned a bachelor’s degree in mechanical engineering from the University of California, Davis. Back to top. John Onopchenko, Director John Onopchenko oversees Johnson & Johnson Development Corporation’s cardiovascular portfolio across all healthcare categories, currently managing investments in 20 companies located primarily in the Western United States. Over the last 20 years, he has progressively increased his responsibilities through the successful development and commercialization of six new-to-the-world technologies, including surgical stapling, endoscopic surgery, medical lasers, and magnetic resonance imaging/spectroscopy. His global leadership experience includes general management, business and product development, operations and supply chain management, and marketing and sales management. He received a master’s degree in business from the University of Chicago and completed the Advanced Management Program at the University of Oxford. He is a member of the Licensing Executive Society and a registered representative with the National Association of Securities Dealers. Back to top. Daniel A. Pelak, Director Thomas Prescott, Director Before joining Align Technologies in 2002, Thomas Prescott was president and chief executive officer of Cardiac Pathways, Inc., and a consultant to Boston Scientific Corporation after its 2001 acquisition of the company. He previously held various sales, general management, and executive positions with Nellcor Puritan Bennett, Inc., management positions at GE Medical Systems, and sales, marketing, and management positions at Siemens. He also serves as a director of privately held R2 Technologies, Inc. He earned a master’s degree from Northwestern University’s Kellogg Graduate School of Management and a bachelor’s degree in civil engineering from Arizona State University. Back to top. Richard S. Stack, M.D., Director In addition to founding Synecor, Dr. Richard Stack has been a prolific educator, researcher, and inventor for more than 20 years. Since 2003, he has been a professor emeritus of medicine in cardiology at Duke University Medical Center, where he completed his fellowship training in cardiology in 1982 and spent his entire academic career. He has authored 360 manuscripts, book chapters, and abstracts, been a principal or co-principal investigator for three National Institutes of Health grants, and received multiple research awards, including the International Award for Best Experimental Researcher in 1995 from Thoraxcenter, the Netherlands. He holds 25 current worldwide patents, with 35 more currently pending for a variety of vascular and therapeutic devices. Back to top. |
Copyright © 2006 IRM, Inc. All rights reserved.
